Cullinan Oncology (CGEM) Stock Forecast, Price Target & Predictions
CGEM Stock Forecast
Cullinan Oncology stock forecast is as follows: an average price target of $32.00 (represents a 78.27% upside from CGEM’s last price of $17.95) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
CGEM Price Target
The average price target for Cullinan Oncology (CGEM) is $32.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $38.00 to $28.00. This represents a potential 78.27% upside from CGEM's last price of $17.95.
CGEM Analyst Ratings
According to 4 Wall Street analysts, Cullinan Oncology's rating consensus is 'Buy'. The analyst rating breakdown for CGEM stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cullinan Oncology Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 08, 2024 | Jeffrey Hung | Morgan Stanley | $38.00 | $16.38 | 131.99% | 111.70% |
| May 16, 2024 | Edward White | H.C. Wainwright | $28.00 | $26.72 | 4.79% | 55.99% |
| Apr 17, 2024 | Kaveri Pohlman | BTIG | $30.00 | $17.32 | 73.21% | 67.13% |
| Apr 16, 2024 | Edward White | H.C. Wainwright | $29.00 | $17.63 | 64.54% | 61.56% |
| Feb 03, 2023 | - | Morgan Stanley | $19.00 | $11.91 | 59.53% | 5.85% |
The latest Cullinan Oncology stock forecast, released on Aug 08, 2024 by Jeffrey Hung from Morgan Stanley, set a price target of $38.00, which represents a 131.99% increase from the stock price at the time of the forecast ($16.38), and a 111.70% increase from CGEM last price ($17.95).
Cullinan Oncology Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 4 |
| Avg Price Target | - | $38.00 | $31.25 |
| Last Closing Price | $17.95 | $17.95 | $17.95 |
| Upside/Downside | -100.00% | 111.70% | 74.09% |
In the current month, the average price target of Cullinan Oncology stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cullinan Oncology's last price of $17.95. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 09, 2024 | William Blair | Outperform | Outperform | Hold |
| Aug 08, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| May 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 17, 2024 | BTIG | Buy | Buy | Hold |
| Apr 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 15, 2024 | William Blair | - | Outperform | Initialise |
| Feb 03, 2023 | Morgan Stanley | Overweight | Overweight | Hold |
Cullinan Oncology's last stock rating was published by William Blair on Aug 09, 2024. The company gave CGEM a "Outperform" rating, the same as its previous rate.
Cullinan Oncology Financial Forecast
Cullinan Oncology Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jul 22 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $18.94M | - |
| Avg Forecast | - | - | - | - | $995.13K | $2.09M | $2.05M | $1.93M | $15.00M | - | - | - | - | $275.00M | $18.92M | $9.00M |
| High Forecast | - | - | - | - | $995.13K | $2.09M | $2.05M | $1.93M | $15.00M | - | - | - | - | $275.00M | $18.92M | $9.00M |
| Low Forecast | - | - | - | - | $995.13K | $2.09M | $2.05M | $1.93M | $15.00M | - | - | - | - | $275.00M | $18.92M | $9.00M |
| # Analysts | - | - | - | - | - | - | - | - | 1 | - | - | 6 | 5 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | - |
Cullinan Oncology's average Quarter revenue forecast for Jul 22 based on 2 analysts is $275.00M, with a low forecast of $275.00M, and a high forecast of $275.00M. CGEM's average Quarter revenue forecast represents a 1351.72% increase compared to the company's last Quarter revenue of $18.94M (Mar 21).
Cullinan Oncology EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jul 22 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | 1 | - | - | 6 | 5 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-45.41M | - | $-55.00K | $-28.33M |
| Avg Forecast | - | - | - | - | $597.08K | $1.26M | $1.23M | $1.16M | $9.00M | - | - | - | - | $165.00M | $-100.18K | $5.40M |
| High Forecast | - | - | - | - | $597.08K | $1.26M | $1.23M | $1.16M | $9.00M | - | - | - | - | $165.00M | $-80.14K | $5.40M |
| Low Forecast | - | - | - | - | $597.08K | $1.26M | $1.23M | $1.16M | $9.00M | - | - | - | - | $165.00M | $-120.22K | $5.40M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.55% | -5.25% |
undefined analysts predict CGEM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Cullinan Oncology's previous annual EBITDA (undefined) of $NaN.
Cullinan Oncology Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jul 22 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | 1 | - | - | 6 | 5 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-23.80M | - | $-70.00K | $-28.35M |
| Avg Forecast | $-39.18M | $-36.65M | $-34.25M | $-33.87M | $-46.38M | $-48.31M | $-47.21M | $-47.34M | $-45.88M | $-44.47M | $-39.92M | $-42.58M | $-41.14M | $232.98M | $-127.50K | $-16.48M |
| High Forecast | $-39.18M | $-36.65M | $-34.25M | $-33.87M | $-46.38M | $-48.31M | $-47.21M | $-47.34M | $-45.88M | $-39.34M | $-39.92M | $-42.58M | $-39.41M | $232.98M | $-102.00K | $-16.48M |
| Low Forecast | $-39.18M | $-36.65M | $-34.25M | $-33.87M | $-46.38M | $-48.31M | $-47.21M | $-47.34M | $-45.88M | $-50.17M | $-39.92M | $-42.58M | $-43.31M | $232.98M | $-153.00K | $-16.48M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.58% | - | 0.55% | 1.72% |
Cullinan Oncology's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CGEM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Cullinan Oncology SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jul 22 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | 1 | - | - | 6 | 5 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $10.56M | - | $5.16M | $12.54M |
| Avg Forecast | - | - | - | - | $1.10M | $2.32M | $2.27M | $2.14M | $16.62M | - | - | - | - | $304.62M | $9.39M | $9.97M |
| High Forecast | - | - | - | - | $1.10M | $2.32M | $2.27M | $2.14M | $16.62M | - | - | - | - | $304.62M | $11.27M | $9.97M |
| Low Forecast | - | - | - | - | $1.10M | $2.32M | $2.27M | $2.14M | $16.62M | - | - | - | - | $304.62M | $7.51M | $9.97M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.55% | 1.26% |
Cullinan Oncology's average Quarter SG&A projection for Mar 24 is -, based on 6 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to CGEM last annual SG&A of $10.56M (Dec 23).
Cullinan Oncology EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jul 22 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | 1 | - | - | 6 | 5 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.56 | - | $-0.00 | $-0.68 |
| Avg Forecast | $-0.71 | $-0.67 | $-0.62 | $-0.62 | $-0.84 | $-0.88 | $-0.86 | $-0.86 | $-0.83 | $-0.81 | $-0.73 | $-0.99 | $-0.96 | $5.42 | $-0.12 | $-0.39 |
| High Forecast | $-0.71 | $-0.67 | $-0.62 | $-0.62 | $-0.84 | $-0.88 | $-0.86 | $-0.86 | $-0.83 | $-0.71 | $-0.73 | $-0.99 | $-0.92 | $5.42 | $-0.12 | $-0.39 |
| Low Forecast | $-0.71 | $-0.67 | $-0.62 | $-0.62 | $-0.84 | $-0.88 | $-0.86 | $-0.86 | $-0.83 | $-0.91 | $-0.73 | $-0.99 | $-1.01 | $5.42 | $-0.12 | $-0.39 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.58% | - | 0.01% | 1.75% |
According to undefined Wall Street analysts, Cullinan Oncology's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CGEM previous annual EPS of $NaN (undefined).
Cullinan Oncology Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ACET | Adicet Bio | $1.49 | $32.50 | 2081.21% | Buy |
| IPSC | Century Therapeutics | $1.60 | $20.00 | 1150.00% | Buy |
| LYEL | Lyell Immunopharma | $1.23 | $9.50 | 672.36% | Hold |
| ZNTL | Zentalis Pharmaceuticals | $3.24 | $21.86 | 574.69% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| VOR | Vor Biopharma | $1.05 | $6.00 | 471.43% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| SANA | Sana Bio | $4.47 | $12.00 | 168.46% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| AUTL | Autolus Therapeutics | $4.08 | $9.50 | 132.84% | Buy |
| OLMA | Olema Pharmaceuticals | $12.70 | $27.00 | 112.60% | Buy |
| LYRA | Lyra Therapeutics | $0.28 | $0.50 | 78.57% | Hold |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| CCCC | C4 Therapeutics | $6.44 | $11.33 | 75.93% | Hold |
| BOLT | Bolt Biotherapeutics | $0.61 | $1.00 | 63.93% | Hold |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
CGEM Forecast FAQ
Is Cullinan Oncology a good buy?
Yes, according to 4 Wall Street analysts, Cullinan Oncology (CGEM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of CGEM's total ratings.
What is CGEM's price target?
Cullinan Oncology (CGEM) average price target is $32 with a range of $28 to $38, implying a 78.27% from its last price of $17.95. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Cullinan Oncology stock go up soon?
According to Wall Street analysts' prediction for CGEM stock, the company can go up by 78.27% (from the last price of $17.95 to the average price target of $32), up by 111.70% based on the highest stock price target, and up by 55.99% based on the lowest stock price target.
Can Cullinan Oncology stock reach $30?
CGEM's average twelve months analyst stock price target of $32 supports the claim that Cullinan Oncology can reach $30 in the near future.
What are Cullinan Oncology's analysts' financial forecasts?
Cullinan Oncology's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $7.07M (high $7.07M, low $7.07M), average EBITDA is $4.24M (high $4.24M, low $4.24M), average net income is $-189M (high $-189M, low $-189M), average SG&A $7.83M (high $7.83M, low $7.83M), and average EPS is $-3.438 (high $-3.438, low $-3.438). CGEM's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-144M (high $-144M, low $-144M), average SG&A $0 (high $0, low $0), and average EPS is $-2.615 (high $-2.615, low $-2.615).
Did the CGEM's actual financial results beat the analysts' financial forecasts?
In terms of the last quarterly report (Mar 2021), Cullinan Oncology's revenue was $18.94M, beating the average analysts' forecast of $18.92M by 0.11%. The company's EBITDA was $-55K, missing the average prediction of $-100K by -45.10%. Cullinan Oncology's net income was $-70K, missing the average estimation of $-128K by -45.10%. The company's SG&A was $5.16M, missing the average forecast of $9.39M by -45.10%. Lastly, the company's EPS was $-0.00167, missing the average prediction of $-0.117 by -98.57%